GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (STU:3DMA) » Definitions » Price-to-Tangible-Book

Kintara Therapeutics (STU:3DMA) Price-to-Tangible-Book : (As of Jun. 05, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Kintara Therapeutics Price-to-Tangible-Book?

As of today (2024-06-05), Kintara Therapeutics's share price is €0.227. Kintara Therapeutics's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was €-0.07. Hence, Kintara Therapeutics's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Kintara Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

During the past 13 years, Kintara Therapeutics's highest Price to Tangible Book Ratio was 291.50. The lowest was 2.85. And the median was 17.28.

STU:3DMA's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.78
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Kintara Therapeutics's share price is €0.227. Kintara Therapeutics's Book Value per Sharefor the quarter that ended in Mar. 2024 was €-0.07. Hence, Kintara Therapeutics's P/B Ratio of today is .


Kintara Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Kintara Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintara Therapeutics Price-to-Tangible-Book Chart

Kintara Therapeutics Annual Data
Trend Dec13 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Kintara Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kintara Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Kintara Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kintara Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Kintara Therapeutics's Price-to-Tangible-Book falls into.



Kintara Therapeutics Price-to-Tangible-Book Calculation

Kintara Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2024 )
=0.227/-0.072
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Kintara Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Kintara Therapeutics (STU:3DMA) Business Description

Traded in Other Exchanges
Address
9920 Pacific Heights Blvd, Suite 150, San Diego, CA, USA, 92121
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Kintara Therapeutics (STU:3DMA) Headlines

No Headlines